GAO finds policy gaps in DEA and FDA drug scheduling process

GAO found that DEA and FDA lack comprehensive procedures for evaluating substances and developing scheduling recommendations, even though DEA aligned with HHS in all 84 finalized actions reviewed. The open recommendations matter to Oklahoma operators because clearer federal procedures could affect the consistency and timing of future marijuana scheduling decisions.